

Use of Insulin Glargine and Metformin for Prevention of Diabetes and its Cardiovascular Complications

Kelleni MT*

Assistant professor of pharmacology, Faculty of Medicine, Minia University, Egypt

***Corresponding author:** Mina T Kelleni, Pharmacology department, Faculty of Medicine, Minia University, Minia, Egypt, Tel: +201200382422; Email: drthabetpharm@yahoo.com

Editorial

Volume 2 Issue 2

Received Date: February 24, 2017

Published Date: March 01, 2017

Editorial

Cardiovascular disease is a common and serious complication of type 2 diabetes mellitus (T2DM) often linked to the increased morbidity and mortality associated with T2DM [1].

It's noteworthy to recall that 30% of contemporary cardiology patients have coexisting known diabetes, and another 40% have either undiagnosed diabetes or pre-diabetes [2].

Two thirds of patients with T2DM can die from heart attack or a cerebrovascular accident if it is not possible to influence these risks by procedures such as decreasing the blood pressure, cholesterol level, glycemia and to stop smoking [3].

Multiple studies have documented that early insulin; insulin glargine in particular, treatment could be used as a strategy in prevention of cardiovascular disease and T2DM progression in pre-diabetes and overt diabetes patients as well as reduction of development of new diabetes from pre-diabetes. Insulin is known to possess cardio protective and potentially anti-atherosclerotic effects [3,4].

Moreover, treatment with insulin glargine was associated with marked improvement in the lipid profile of people with T2DM [1]. On the other hand, Metformin is the most widely recommended first-line drug therapy in T2DM, also in terms of preventing cardiovascular complications [2].

Insulin glargine treatment combined with Metformin in the early stages of diabetes has been shown to be a safe protocol without an increased number of atherosclerosis or cancer occurrences, and with minimal weight gain [5,6]. The decision to introduce

basal insulin to Metformin must, however be individualized based on a risk-benefit analysis [7].

References

1. Dailey G, Wang E (2014) A review of cardiovascular outcomes in the treatment of people with type 2 diabetes. *Diabetes Ther* 5(2): 385-402.
2. Standl E, Erbach M, Schnell O (2013) Glycemic control: a combination of lifestyle management and the use of drugs. *Cardiol Ther* 2(1): 1-16.
3. Adamikova A, Rybka J (2013) Up to day trends in insulin therapy. *Vnitr Lek* 59(6): 440-443.
4. Roman G, Hancu N (2009) Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. *Horm Metab Res* 41(2): 116-122.
5. Rusavy Z, Lacigova S, Kvapil M (2013) What has the largest study in the history of diabetology brought us? *Vnitr Lek* 59(3): 160-164.
6. Svacina S (2011) Is there any relation between diabetes therapy and cancer risk? *Vnitr Lek* 57(9): 760-763.
7. Hanefeld M, Monnier L, Schnell O, Owens D (2016) Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials. *Diabetes Ther* 7(2): 187-201.